title: Genetic variation in soluble epoxide hydrolase: association with outcome after aneurysmal subarachnoid hemorrhage.
abstract: OBJECTIVE
  Patients with aneurysmal subarachnoid hemorrhage (SAH) are at high risk for delayed cerebral ischemia (DCI) and stroke. Epoxyeicosatrienoic acids (EETs) play an important role in cerebral blood flow regulation and neuroprotection after brain injury. Polymorphisms in the gene for the enzyme soluble epoxide hydrolase (sEH), which inactivates EETs, are associated with ischemic stroke risk and neuronal survival after ischemia. This prospective observational study of patients with SAH compares vital and neurologic outcomes based on functional polymorphisms of sEH.
  
  
  METHODS
  Allelic discrimination based on quantitative real-time polymerase chain reaction was used to differentiate wild-type sEH from K55R heterozygotes (predictive of increased sEH activity and reduced EETs) and R287Q heterozygotes (predictive of decreased sEH activity and increased EETs). The primary outcome was new stroke after SAH. Secondary outcomes were death, Glasgow Outcome Scale score, and neurological deterioration attributable to DCI.
  
  
  RESULTS
  Multivariable logistic regression models adjusted for age at admission and Glasgow Coma Scale scores revealed an increase in the odds of new stroke (OR 5.48 [95% CI 1.51-19.91]) and death (OR 7.52 [95% CI 1.27-44.46]) in the K55R group, but no change in the odds of new stroke (OR 0.56 [95% CI 0.16-1.96]) or death (OR 3.09 [95% CI 0.51-18.52]) in patients with R287Q genotype, compared with wild-type sEH. The R287Q genotype was associated with reduced odds of having a Glasgow Outcome Scale score of ≤ 3 (OR 0.23 [95% CI 0.06-0.82]). There were no significant differences in the odds of neurological deterioration due to DCI.
  
  
  CONCLUSIONS
  Genetic polymorphisms of sEH are associated with neurological and vital outcomes after aneurysmal SAH.
authors.affiliation: Departments of Anesthesiology & Perioperative Medicine and.
authors.forename: Ross P
authors.initials: RP
authors.lastname: Martini
authors.forename: Jonathan
authors.initials: J
authors.lastname: Ward
authors.forename: Dominic A
authors.initials: DA
authors.lastname: Siler
authors.forename: Jamie M
authors.initials: JM
authors.lastname: Eastman
authors.forename: Jonathan W
authors.initials: JW
authors.lastname: Nelson
authors.forename: Rohan N
authors.initials: RN
authors.lastname: Borkar
authors.forename: Nabil J
authors.initials: NJ
authors.lastname: Alkayed
authors.forename: Aclan
authors.initials: A
authors.lastname: Dogan
authors.forename: Justin S
authors.initials: JS
authors.lastname: Cetas
mesh_terms: D000328:Adult; D000368:Aged; D004851:Epoxide Hydrolases / Q000235:genetics*; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D020022:Genetic Predisposition to Disease / Q000453:epidemiology / Q000235:genetics; D014644:Genetic Variation; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D017354:Point Mutation; D011110:Polymorphism, Genetic; D012307:Risk Factors; D020521:Stroke / Q000235:genetics / Q000401:mortality / Q000628:therapy; D013345:Subarachnoid Hemorrhage / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D016896:Treatment Outcome; D020301:Vasospasm, Intracranial / Q000235:genetics / Q000401:mortality / Q000628:therapy
chemical_list: D004851:Epoxide Hydrolases; C506428:EPHX2 protein, human
keywords: ARDS = acute respiratory distress syndrome; CBF = cerebral blood flow; CSW = cerebral salt wasting; DCI = delayed cerebral ischemia; EET = epoxyeicosatrienoic acid; EVD = extraventricular drain; GCS = Glasgow Coma Scale; GOS = Glasgow Outcome Scale; ICU = intensive care unit; IQR = interquartile range; SAH = subarachnoid hemorrhage; SAPS II = Simplified Acute Physiology Score; SIADH = syndrome of inappropriate secretion of antidiuretic hormone; TCD = transcranial Doppler; WBC = white blood cell; WT = wild type; epoxyeicosatrienoic acids; qPCR = quantitative polymerase chain reaction; sEH = soluble epoxide hydrolase; soluble epoxide hydrolase; subarachnoid hemorrhage; vascular disorders